Pro 2013-018 (Jianfeng Group's Announcement on Corporate Bond Issuance in 2013)-2
Release time:
2020-08-05
6 , Placing
The lead underwriter will place all valid subscriptions based on the results of the offline inquiry, and the amount of the placement received by institutional investors will not exceed the corresponding maximum subscription amount in their valid subscriptions. The placement is based on the following principles: bookkeeping and filing according to the investor's subscription rate from low to high, the subscription amount is accumulated according to the subscription rate from low to high, and the highest subscription rate corresponding to the total amount of the bond issue is recognized as the issue rate when the accumulated amount exceeds or is equal to the total amount of the bond issue.
In this placement process, investors whose subscription interest rate is below the final issue interest rate will be placed in accordance with the principle of price priority; in the case of the same subscription interest rate, the sponsor (lead underwriter) has the right to decide long-term cooperation Investors are given priority. At the same time, the issuer and the lead underwriter have the right to determine the final placement results of the bonds.
7 , Funds Transfer
Investors who receive the placement shall pay the subscription money in a timely manner according to regulations. The subscription money shall be paid in 201 3 6 7 ( T 2 ) 16:00 before is transferred in full to the receiving bank account designated by the sponsor (lead underwriter). Please indicate the words "Investor Short" and "Jianfeng Group Corporate Bond Subscription Fund " when making the payment, and fax the payment voucher to the sponsor (lead underwriter).
Collection Account Name |
Zhejiang Securities Co., Ltd. |
Collection Account Account |
1202020629900012522 |
Collection Account Opening Bank |
Industrial and Commercial Bank of China Hangzhou Hushu Sub-branch |
Collection Bank Address |
Hangzhou Gongshu District Hushu South Road 377 |
City Exchange Number |
206 |
large payment system line number |
102331002069 |
receiving bank contact |
Chen Li, Guo Jian |
collection Bank Contact Phone |
0571-88377080 , 88377084 |
8 , Online Issuance Registration
Sponsor (Lead Underwriter) According to the Online Issuance Results, the registration data issued offline shall be submitted to the Shanghai Stock Exchange in the form of written and electronic data before the 10:30 on the# of the 201 3 April 13 day (T 3 day). At the same time, electronic data shall be generated as required and submitted to the registration company for registration.
9 , default recognition purchase processing
pair failed to 185 on 201 3 July 7 ( T 2 ) 1 6: investors who have paid their subscriptions in full before 00 will be deemed to have defaulted on the subscription and the sponsor (lead underwriter) has the right to cancel their subscriptions. The sponsor (lead underwriter) has the right to dispose of all the bonds under the 201 offer of the defaulting investor , and has the right to further pursue the legal liability of the defaulting investor in accordance with the law.
, Risk Disclosure
Issuer and Sponsor (Lead Underwriter) have fully disclosed the possible risks involved in this issue on Known Scope . For detailed risk disclosure terms, please refer to "Zhejiang Jianfeng Group Co., Ltd. Public Issuance of Corporate Bonds (Phase I) Prospectus".
6 , Subscription Fee
No commission, transfer fee, stamp duty and other fees will be charged to investors for this issue.
7 , Issuer and Sponsor (Lead Underwriter)
Fa Line : Zhejiang Jianfeng Group Co., Ltd.
Registered Address: Wujiang East Road, Jinhua City, Zhejiang Province 88
Lian Department : Zhu Jianwei, Fu Zhijian
Tel: 0579-82320582 , 82303537
Fax: 0579-82320582
Postal Code: 321000
sponsor (lead underwriter): Zhejiang securities co., ltd.
registered address: Hangzhou hangda road 274
Lian department : Yu Jianxia , Hu Fangchao
Consultation Tel: 0571-8790 1941 , 8790 3138 ;
Purchase Fax: 0571-87902749 , 87903769
Postal Code: 310007
(this page has no text and is the cover chapter page of Zhejiang Jianfeng Group Co., Ltd. 201 3 Corporate Bonds (Phase I) Issuance Announcement )
Issuer: Zhejiang Jianfeng Group Co., Ltd.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page